Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Oxidative stress has been reported to play a role in melasma pathophysiology. The objective
of the study is to compare oral superoxide dismutase (GLISODin) to placebo, in combination to
sunscreen to decrease melasma severity.